Recent Achievements

Research

 >>Research overview
 
 >>Research Areas
 
 >>Recent Achievements
 
 >>Research platforms
 
 >>Facilities
 
 >>Exchange & Collaboration

Recent Achievements

Enamine N-Oxide-Modified Transcytosis-Triggering Nanoparticles Overcome Stromal Barriers and Remodel Immunosuppressive Microenvironment in Pancreatic Cancer Combination Therapy

2025/02/24

In pancreatic ductal adenocarcinoma (PDAC), stromal cells and matrix proteins form a dense physical barrier that not only confines tumor cells but also severely restricts the penetration of therapeutic agents and CD8+ T lymphocytes. Concurrently, the hyperactivated TGF-β/SMAD signaling pathway furt...

Read More
Advanced Science丨Team Led by Assoc. Prof. Tao Sun and Prof. Chen Jiang: Nanoregulator Targeting Tumor Methionine Metabolism and Epigenetics

2025/02/24

Epigenetic dysregulation in tumors has been established as a pivotal driver of malignant progression, therapeutic resistance, and the formation of a pro-tumor immune microenvironment, mediated through its influence on gene expression and metabolic reprogramming. This uncontrolled metabolic pattern, ...

Read More
Nature Communications | Professor Wei Lu in collaboration with research group of Shanghai Jiao Tong University School of Medicine identified a new mechanism of tumor resistance to adoptive macrophage therapy

2025/01/27

Adoptive macrophage therapy has emerged as a promising strategy to combat solid tumors due to the phenotypic plasticity of macrophages, the tumor-penetrating capacity and the ability to modulate the tumor microenvironment. Currently, various genetic approaches have been developed to engineer macroph...

Read More
Angew. Chem.: Microbe Engineering to Provide Drimane-Type Building Blocks for Chiral Pool Synthesis of Meroterpenoids

2025/01/18

Drimane-type merosesquiterpenoids (DMT) are a class of natural products with diverse structures and broad biological activity. Classical DMT synthesis relies on atom-inefficient plant-derived chiral pool building blocks, while alternative drimane-type building blocks such as drimenol and albicanol o...

Read More
Advanced Materials丨"Nano-Dredger" Facilitates Waste Clearance in Alzheimer's Disease

2025/01/07

A breakthrough study conducted by Professor Qizhi Zhangs group from the School of Pharmacy at Fudan University has unveiled a novel Nano-dredger technology that addresses axonal autophagic dysfunction—a key pathological feature of Alzheimers disease (AD). The research highlights how axonal autophago...

Read More
Biomaterials | Jianxin Wang's Group Develops Antigen Self-Presenting Dendrosome Nanovaccines for Cancer Immunotherapy

2025/01/07

Recently, Professor Jianxin Wangs group at the School of Pharmacy, Fudan University, successfully developed an antigen self-presenting dendrosome nanovaccine. Through the synergistic co-delivery of antigens and STING agonists, this novel vaccine substantially enhances the efficacy of cancer immunoth...

Read More
J Control Release | PROTAC Delivery in Tumor Immunotherapy : Where Are We and Where Are Going?

2024/12/20

In the context of the immune microenvironment characteristics of cold tumors, PROTACs has demonstrated unique advantages, including solving drug resistance problems and non-patent drug targets. However, there is still a lack of complete guidance reviews on targeted PROTAC drug delivery systems that ...

Read More
Advanced Materials丨Biomimetic Nanomotors in Neuroprotective Therapy of Ischemic Stroke

2024/12/12

Stroke has become the second reason of death and the third reason of disability in the world, of which ischemic stroke accounts for more than 80% of cases. Nerve injury represents the primary reason of high mortality and disability as well as poor prognosis of ischemic stroke, and its mechanisms inv...

Read More
JMC | Professor Wei Fu's Team at School of Pharmacy, Fudan University Reported Novel RORγt Inverse Agonists for the Treatment of Psoriasis

2024/12/10

Recently, Professor Wei Fu’s team from the School of Pharmacy at Fudan University published a research paper titled “Discovery of Novel N-Sulfonamide-tetrahydroquinolines as Potent Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists for the Treatment of Psoriasis” in Jour...

Read More
JACS | Concise Synthesis of Norzoanthamine Enabled by a Set of Photochemical Reactions

2024/11/20

Sun research group has recently developed an efficient total synthesis of marine alkaloid norzoanthamine. The related results have been published online in Journal of the American Chemical Society(JACS), entitled Concise Synthesis of Norzoanthamine Enabled by a Set of Photochemical Transformations.Z...

Read More
Professor Yingxia Li’s Group Reported the Discovery of a Novel p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma

2024/10/24

E1A binding protein (p300) and CREB binding protein (CBP), described as p300/CBP, are two highly homologous and multidomainhistone acetyltransferases. The bromodomain (BRD) and catalytic domain of p300/CBP synergistically regulate the level of the acetylated lysine of histone, which impacts related ...

Read More
A Peptide-Drug Conjugate-Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced-Stage Alzheimer's Disease

2024/10/10

Alzheimers disease (AD) is a progressive neurodegenerative disease. However, there is currently a lack of effective treatments to inhibit its progression, making it one of the most challenging brain diseases to treat clinically. Recent studies have shown that the phenotype and metabolic function of ...

Read More
JMC｜Research Team Led by Professor Xianfeng Gu Discovers Promising NLRP3 Inhibitor for Treating Inflammatory Bowel Disease

2024/09/25

Recently, a study on “design, synthesis and bioevaluation of novel NLRP3 inhibitor with IBD immunotherapy from the virtual screen” has been published in the Journal of Medicinal Chemistryby Professor Xianfeng Gus group from school of pharmacy，Fudan University. In this work, the research team used...

Read More
The research teams led by Zhiqing Pang and Jianxin Wang from Fudan University School of Pharmacyin collaboration with Dr. Dongsheng Li’s group of Microsoft Research Asia (Shanghai) achieved new advancements in the field of AI-empowered drug di

2024/09/02

Traditional drug development faces challenges such as low success rates, high costs and lengthy development cycles, which necessitates the adoption of new technologies and models to change the status quo. The application of various omics technologies in patient cohort can reveal patient disease char...

Read More
Nat. Biotechnol.|Recent Progress in the in Vivo Raman Imaging of Prof. Wei Lu from Fudan University School of Pharmacy in Collaboration with Prof. Zeyu Xiao from Shanghai JiaoTong University and Prof. Xiaohong Fang from CAS Hangzhou Institute of Medi

2024/09/02

Raman spectroscopy is widely used in chemical analysis, material sciences, and biomedical research due to its high specificity and fingerprint spectroscopy. Spontaneous Raman imaging of small molecules is often insensitive, with Raman scattering occurring in only 1 in 10 million incident photons. As...

Read More
JACS | Dr Lu Wang’s Group Developed a Chemigenetic Probe for Monitoring NADPH Dynamics in Living Cells

2024/08/21

Dr Wang’s group at School of Pharmacy, Fudan University, has recently developed a chemigenetic probe designed for monitoring NADPH dynamics in living cells. The research article was published in Journal of the American Chemical Societytitled Fluorogenic rhodamine-based chemigenetic biosensor for mo...

Read More
Autophagy News Release

2024/08/21

On June 19, 2024, the research team of Professor Xuemei Zhang, Department of Pharmacology, School of Pharmacy, Fudan University, published a paper in Autophagy (2024 IF: 14.6). The title of the research paper is “Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochond...

Read More
JMC｜Professor Yang Wang's Group Discovered Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Anti-multidrug Resistance Efficacy

2024/08/21

Microtubules constitute a major component of the cellular cytoskeleton. Malignant tumor cells exhibit robust proliferation and highly active mitosis, making microtubules one of the most successful targets for anticancer therapy. Despite the availability of several marketed microtubule-targeting agen...

Read More
Reconciling the Cooperative-Competitive Patterns Among Tumor and Immune Cells for Triple-Negative Breast Cancer Treatment Using Multimodule Nanocomplexes

2024/04/29

The intricate interplay between tumor cells, neighboring immune cells, and various immune cell types involves complex competitive-cooperative patterns rewired through metabolic and immune signals, which are essential for shaping the immunosuppressive tumor microenvironment (TME). This metabolic imba...

Read More
Professor Li Yingxia’s Group Reported a Novel Class of p300/CBP PROTAC Degraders with Anti-Hepatocellular Carcinoma Activity

2024/03/05

Histone acetylation is one of the epigenetic regulation within cells, which is important for gene transcription, DNA replication, and DNA damage repair. This chemical modification is dynamically modulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). E1A associated protein p...

Read More

firstpage <<previouspage nextpage>> endpage
PageNumber 1/5

杏悦专业提供：杏悦、、等服务，提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等，界面美观优质完美，安全稳定，服务一流👳🏽‍♀️，杏悦欢迎您。杏悦官网xml地图

Enamine N-Oxide-Modified Transcytosis-Triggering Nanoparticles Overcome Stromal Barriers and Remodel Immunosuppressive Microenvironment in Pancreatic Cancer Combination Therapy

Advanced Science丨Team Led by Assoc. Prof. Tao Sun and Prof. Chen Jiang: Nanoregulator Targeting Tumor Methionine Metabolism and Epigenetics

Nature Communications | Professor Wei Lu in collaboration with research group of Shanghai Jiao Tong University School of Medicine identified a new mechanism of tumor resistance to adoptive macrophage therapy

Angew. Chem.: Microbe Engineering to Provide Drimane-Type Building Blocks for Chiral Pool Synthesis of Meroterpenoids

Advanced Materials丨"Nano-Dredger" Facilitates Waste Clearance in Alzheimer's Disease

Biomaterials | Jianxin Wang's Group Develops Antigen Self-Presenting Dendrosome Nanovaccines for Cancer Immunotherapy

J Control Release | PROTAC Delivery in Tumor Immunotherapy : Where Are We and Where Are Going?

Advanced Materials丨Biomimetic Nanomotors in Neuroprotective Therapy of Ischemic Stroke

JMC | Professor Wei Fu's Team at School of Pharmacy, Fudan University Reported Novel RORγt Inverse Agonists for the Treatment of Psoriasis

JACS | Concise Synthesis of Norzoanthamine Enabled by a Set of Photochemical Reactions

Professor Yingxia Li’s Group Reported the Discovery of a Novel p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma

A Peptide-Drug Conjugate-Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced-Stage Alzheimer's Disease

JMC｜Research Team Led by Professor Xianfeng Gu Discovers Promising NLRP3 Inhibitor for Treating Inflammatory Bowel Disease

The research teams led by Zhiqing Pang and Jianxin Wang from Fudan University School of Pharmacyin collaboration with Dr. Dongsheng Li’s group of Microsoft Research Asia (Shanghai) achieved new advancements in the field of AI-empowered drug di

Nat. Biotechnol.|Recent Progress in the in Vivo Raman Imaging of Prof. Wei Lu from Fudan University School of Pharmacy in Collaboration with Prof. Zeyu Xiao from Shanghai JiaoTong University and Prof. Xiaohong Fang from CAS Hangzhou Institute of Medi

JACS | Dr Lu Wang’s Group Developed a Chemigenetic Probe for Monitoring NADPH Dynamics in Living Cells

Autophagy News Release

JMC｜Professor Yang Wang's Group Discovered Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Anti-multidrug Resistance Efficacy

Reconciling the Cooperative-Competitive Patterns Among Tumor and Immune Cells for Triple-Negative Breast Cancer Treatment Using Multimodule Nanocomplexes

Professor Li Yingxia’s Group Reported a Novel Class of p300/CBP PROTAC Degraders with Anti-Hepatocellular Carcinoma Activity